Selinisol (Silvio) generally requires several courses of treatment to be effective

Selinexor is a selective nuclear export inhibitor (SINE). It mainly inhibits the function of nuclear export protein XPO1, allowing tumor suppressor proteins to remain in the nucleus, thereby reactivating anti-cancer signaling pathways and inducing cancer cell apoptosis. The drug has been approved for use in relapsed/refractory multiple myeloma and diffuse large Bcell lymphoma. Due to its unique mechanism of action, the efficacy is not immediately apparent, and it generally takes a certain course of treatment to observe an objective oncological response.

Judging from clinical trial data, some patients can show signs of improvement in hematological indicators or tumor shrinkage after taking 2–3 courses of treatment (approximately 1–2 months). For example, in studies of multiple myeloma, some patients can achieve partial remission or stable disease in the second course of treatment. However, it should be pointed out that individual differences are large, and some patients may have to persist for 3–4 courses of treatment before they can observe significant effects. Therefore, doctors usually comprehensively evaluate the efficacy after multiple cycles, rather than drawing conclusions on a single course of treatment.

In actual clinical applications, selinisodol is used in combination with other drugs, such as dexamethasone, bortezomib, etc., to enhance efficacy and delay drug resistance. This combination of regimens often results in faster treatment in the early stages. Under normal circumstances, if there is still no sign of efficacy after 2–3 courses of treatment, the doctor will decide whether to continue treatment or adjust the plan based on factors such as disease progression, patient tolerance, and alternative options. Therefore, the time to effect depends not only on the drug itself, but also on the combination regimen and the patient's specific circumstances.

It needs to be particularly emphasized that the adverse reactions of selinesol are relatively obvious, such as loss of appetite, nausea, fatigue, decreased platelets, etc. Some patients may adjust the dose in advance or even suspend treatment due to side effects. In order to ensure a sufficient course of treatment and observe the efficacy of the drug, patients should strictly follow the doctor's instructions and perform supportive treatment and side effect management under the guidance of the doctor. In general, selinesol usually requires 2–3 courses of treatment to observe the effect, but the optimal number of courses and timing of efficacy evaluation should be comprehensively judged by professional doctors combined with the patient's clinical condition.

Reference link:https://www.drugs.com